

NOVADEL PHARMA INC  
Form 8-K  
March 16, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported) March 14, 2005**

**NOVADEL PHARMA INC.  
(Exact Name of Registrant as Specified in Its Charter)**

---

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-32177  
(Commission File No.)**

**22-2407152  
(I.R.S. Employer  
Identification No.)**

**25 Minneakoning Road  
Flemington, New Jersey 08822  
(Address of principal executive offices) (Zip Code)**

**(908) 782-3431  
(Registrant's telephone number, including area code)**

**N/A  
(Former name or former address, if changed since last report)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
..

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure.**

On March 14, 2005 the Company issues a press release to announce that NovaDel Pharma Inc. would present at the Investing & Partnering in Biotech Forum. The Company hereby incorporates by reference herein the information set forth in the slide presentation to be presented at the forum, a copy of which is attached hereto as Exhibit 99.1. The full text of the press release is set forth in Exhibit 99.2.

**Item 8.01. Other Events**

On March 16, 2005, the Company issued a press release to announced positive results from a pilot pharmacokinetic trial in healthy human subjects that was conducted using it's proprietary lingual spray technology to deliver ondansetron hydrochloride --- the active ingredient marketed under the brand name Zofran® by GlaxoSmithKline for the treatment of chemotherapy-induced nausea and vomiting. The full text of the press release is set forth in Exhibit 99.3 hereto.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Slide Presentation used at March 16, 2005 Investing & Partnering in Biotech Forum.

99.2 Press release dated March 14, 2005, titled "NovaDel Pharma Inc. to Present at the Investing & Partnering in Biotech Forum."

99.3 Press Release dated March 16, 2005, titled "NovaDel Pharma Inc. Announces Positive Pharmacokinetic Study Results of Ondansetron Lingual Spray."

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**NovaDel Pharma Inc.**

By: /s/ Jean W. Frydman

---

Name: Jean W. Frydman  
Title: Vice President, General Counsel  
and Corporate Secretary

Date: March 16, 2005